Inevitably, there have been substantial changes in the management of BRCA1 and BRCA2 mutation carriers since the recruitment period of this study, including the exploration in trials of systemic therapies that exploit BRCA-null tumours, including platinum-based drugs and PARP inhibitors. Here, BRCA2 is linked to neoplasm.